title: Beyond Chemotherapy: An Overview and Review of Targeted Therapy in Cervical Cancer.
abstract: OBJECTIVE
  The purpose of this study was to provide an overview of current and up and coming targeted therapies in cervical cancer with or without chemotherapy.
  
  
  METHODS
  We reviewed the literature using search terms cervical cancer AND immunotherapy, immune therapy, vaccines, bevacizumab, anti-angiogenic therapy, and PARP inhibitors on PubMed. We included all review articles and prospective trials. We also reviewed ClinicalTrials.gov for trials in progress.
  
  
  RESULTS
  The addition of bevacizumab has improved the overall survival of women with advanced or recurrent cervical cancer when compared with cytotoxic therapy alone. This advancement has sparked an interest in other anti-angiogenic agents. Additionally, targeted therapies, including tyrosine kinase inhibitors, immunotherapy, and vaccine therapy, are also being evaluated. Another exciting area of study is the role of poly (ADP-ribose) polymerase inhibition in cervical cancer.
  
  
  CONCLUSIONS
  Though the results are promising, the data are preliminary and additional studies evaluating the proper combination of therapy, dosing, and schedules will help inform the ideal regimen.
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio.
authors.forename: Sarah M
authors.initials: SM
authors.lastname: Crafton
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio. Electronic address: ritu.salani@osumc.edu.
authors.forename: Ritu
authors.initials: R
authors.lastname: Salani
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007167:Immunotherapy; D058990:Molecular Targeted Therapy; D000067856:Poly(ADP-ribose) Polymerase Inhibitors / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D019496:Cancer Vaccines; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D047428:Protein Kinase Inhibitors; D000068258:Bevacizumab
keywords: PARP inhibitors; anti-angiogenesis; cervical cancer; immunotherapy; targeted therapy